Clinical trial for Nasolacrimal Duct Obstruction
Official title Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
ClinicalTrials.gov ID: NCT05999630
What this study is testing
What is Artificial Tears Methylcellulose?
An investigational eye drop being studied for preventing nasolacrimal duct obstruction after radioactive iodine therapy for thyroid cancer.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether using artificial tears after radioactive iodine treatment reduces tear duct blockage over two years.
- Who it's for
- You may be able to join if you have thyroid cancer and will receive radioactive iodine therapy.
- What's involved
- You will use artificial tears at home after each radioactive iodine treatment. You will have check‑ins with the study team to report any eye problems.
- Time commitment
- The study lasts two years, with regular visits to the clinic and daily use of artificial tears at home.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older. Healthy volunteers may be eligible.
You may be able to join if
- Radio-iodine therapy for thyroid cancer
- Radioiodine therapy ≥150 mCi
- Age 18 or older
You likely can't join if
- Use of eye drops, other than artificial tears
- History of periocular trauma with tear duct involvement/lacrimal gland trauma
- History of lacrimal drainage disease: canaliculitis, dacryocystitis
- Prior radiotherapy
- Current or prior use of chemotherapy drugs (i.e. 5-fluorouracil, docetaxel)
- Medical conditions that predispose to NLD stenosis (i.e. sarcoidosis, granulomatosis with polyangiitis, chronic lymphocytic leukemia)
See the full eligibility criteria
- Radio-iodine therapy for thyroid cancer
- Radioiodine therapy ≥150 mCi
- Age 18 or older
- Use of eye drops, other than artificial tears
- History of periocular trauma with tear duct involvement/lacrimal gland trauma
- History of lacrimal drainage disease: canaliculitis, dacryocystitis
- Prior radiotherapy
- Current or prior use of chemotherapy drugs (i.e. 5-fluorouracil, docetaxel)
- Medical conditions that predispose to NLD stenosis (i.e. sarcoidosis, granulomatosis with polyangiitis, chronic lymphocytic leukemia)
- Nasolacrimal duct obstruction at baseline
The study team makes the final eligibility decision.
Where it is enrolling
- Nashville, Tennessee, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Nashville, Tennessee, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.